UK – Pfizer’s RSV vaccine granted MHRA approval to protect infants and older adults

Pfizer’s Abrysvo has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as the first respiratory syncytial virus (RSV) vaccine to protect both infants through maternal immunisation and older adults.

RSV is a common contagious virus characterised by several mild, cold-like symptoms. Although most people recover within a week or two, the virus can cause severe illness in young infants and older adults.

In England, about 15,000 yearly hospital admissions in infants aged under six months are associated with RSV, while the virus is estimated to cause 14,000 hospitalisations in older adults every year in the UK…